CritiTech cancer drug to be tested on dogs
An area pharmaceutical firm has signed a deal with the University of Missouri in hopes of developing a drug to treat cancer in dogs.
Lawrence-based CritiTech Inc. has reached an agreement with the Missouri College of Veterinary Medicine to study whether its drug Nanotax can be used in canines.
CritiTech, 1321 Wakarusa Drive, has long been developing Nanotax to treat cancer in human patients. But the company also believes the drug has potential for veterinary use.
The deal with the University of Missouri will allow veterinarians to begin testing different dosage levels on dogs.
CritiTech leaders expect the study to take about 18 months to complete.
City Government
City of Lawrence ‘assessing options’ in the wake of racist and antisemitic hate speech shared at recent commission meeting
City of Lawrence campsite reporting form has received 230 reports since October; only 57 campsites confirmed
City Commission meeting interrupted by racist, antisemitic hate speech
Lawrence City Commission set for light agenda this week
Campers who remain at North Lawrence site after closing date will be trespassed, but city doesn’t expect that to happen
